Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Lammert

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Hepatology Communications|May 23, 2023
Circulating cell-free messenger RNA secretome characterization of primary sclerosing cholangitisNaga Chalasani, Raj Vuppalanchi, Craig Lammert, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 6, 2012
Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantationStepan Sembera, Craig Lammert, Jayant A Talwalkar, et al.
Hepatology Communications|May 14, 2025
Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registryRichard Dean, Maryam Yazdanfar, Joseph Zepeda, et al.
Journal of Hepatology|September 24, 2022
Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injuryNaga Chalasani, Yi-Ju Li, Andrew Dellinger, et al.
The American Journal of Gastroenterology|August 6, 2023
Thirty-Day Readmissions Are Largely Not Preventable in Patients With CirrhosisEric S Orman, Archita P Desai, Marwan S Ghabril, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 11, 2026
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year AnalysisAdrielly Martins, Anish Reddy, Richard Dean, et al.
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Journal of Autoimmunity|September 11, 2022
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisCumali Efe, Koray Taşçılar, Alessio Gerussi, et al.
Hepatology (Baltimore, Md.)|March 13, 2021
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter StudyCumali Efe, Renumathy Dhanasekaran, Craig Lammert, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Hepatology Communications|May 23, 2023
Circulating cell-free messenger RNA secretome characterization of primary sclerosing cholangitisNaga Chalasani, Raj Vuppalanchi, Craig Lammert, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 6, 2012
Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantationStepan Sembera, Craig Lammert, Jayant A Talwalkar, et al.
Hepatology Communications|May 14, 2025
Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registryRichard Dean, Maryam Yazdanfar, Joseph Zepeda, et al.
Journal of Hepatology|September 24, 2022
Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injuryNaga Chalasani, Yi-Ju Li, Andrew Dellinger, et al.
The American Journal of Gastroenterology|August 6, 2023
Thirty-Day Readmissions Are Largely Not Preventable in Patients With CirrhosisEric S Orman, Archita P Desai, Marwan S Ghabril, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 11, 2026
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year AnalysisAdrielly Martins, Anish Reddy, Richard Dean, et al.
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Journal of Autoimmunity|September 11, 2022
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisCumali Efe, Koray Taşçılar, Alessio Gerussi, et al.
Hepatology (Baltimore, Md.)|March 13, 2021
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter StudyCumali Efe, Renumathy Dhanasekaran, Craig Lammert, et al.
Pageof 6